Iodine or Not (IoN) for Low-risk Differentiated Thyroid Cancer: The Next UK National Cancer Research Network Randomised Trial following HiLo

Clinical Oncology

Volumn 24, Issue 3, 2012, Pages 159-161

  Mallick, U ^a   Harmer, C ^b   Hackshaw, A ^c   Moss, L ^d  

^a FREEMAN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ASPIRATION BIOPSY; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; EDITORIAL; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THYROIDECTOMY; ULTRASOUND; UNITED KINGDOM;

CELL DIFFERENTIATION; GREAT BRITAIN; HUMANS; IODINE RADIOISOTOPES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 84857923706     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.01.001     Document Type: Editorial

References (23)

1. Cancer Research UK, Cancer Statistics. Available at: [accessed 07.11]. http://info.cancerresearchuk.org/cancerstats/types/thyroid.
2. American Cancer Society. Cancer facts and figures, Atlanta: American Cancer Society; 2011. pp. 21, P 1-55.
3. National Cancer Institute. [accessed 07.11]. http://www.cancer.gov/cancertopics/types/thyroid.
4. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
5. Guidelines for the management of thyroid cancer 2007, British Thyroid Association, Royal College of Physicians, London. 2nd ed.
6. Haymart M.R., Banerjee M., Stewart A.K., Koenig R.J., Birkmeyer J.D., Griggs J.J. Use of radioactive iodine for thyroid cancer. JAMA 2011, 306(7):721-728.
7. Iyer N.G., Morris L.G., Tuttle R.M., Shaha A.R., Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer Oct 1, 2011, 117(19):4439-4446.
8. Mallick U.K. The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer: an evidence-based risk-adapted approach. Clin Oncol (R Coll Radiol) 2010, 22(6):472-474. [Special Issue Thyroid Cancer].
9. Tala H., Tuttle R.M. Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010, 22(6):419-429. [Special Issue Thyroid Cancer].
10. Mallick U, Clarke S, Moss L, et al. HiLo: Multicentre randomised phase III clinical trial of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer. International Thyroid Congress, Paris, France 2010.
11. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97(5):418-428.
12. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006, 94(8):692-700.
13. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006, 16(12):1229-1242.
14. Ross D.S., Litofsky D., Ain K.B., et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009, 19:1043-1048.
15. Sawka A.M., Brierley J.D., Tsang R.W., et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008, 37:457-480.
16. Mazzaferri E. A randomized trial of remnant ablation - in search of an impossible dream?. J Clin Endocrinol Metab 2004, 89:3662-3664.
17. Vaisman F., Shaha A., Fish S., Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol 2011, [Epub ahead of print]. 10.1111/j.1365-2265.2011.04002.x.
18. Schlumberger M., Borget I., Nascimento C., Brassard M., Leboulleux S. Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol 2011, 7(10):625-628. 10.1038/nrendo.2011.133.
19. Spencer C., Fatemi S., Singer P., Nicoloff J., Lopresti J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010, 20:587-595.
20. Elisei R., Ugolini C., Viola D., et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949.
21. Kim T.H., Park Y.J., Lim J.A., et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer Aug 31, 2011, [Epub ahead of print]. 10.1002/cncr.26500.
22. Damante G., Scaloni A., Tell G. Thyroid tumors: novel insights from proteomic studies. Expert Rev Proteomics 2009, 6:363-376.
23. Cheng S., Serra S., Mercado M., Ezzat S., Asa S.L. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 2011, 17(8):2385-2394.